Cardiovascular Outcomes in Trials of New Antidiabetic Drug Classes
Type 2 diabetes is among the most prevalent chronic diseases worldwide and the prevention of associated cardiovascular complications is an important treatment goal. Sodium–glucose co-transporter 2 (SGLT2) inhibitors, glucagon-like peptide 1 (GLP-1) receptor agonists and dipeptidyl peptidase-4 (DPP-4...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Radcliffe Medical Media
2021-03-01
|
Series: | Cardiac Failure Review |
Online Access: | https://www.cfrjournal.com/articleindex/cfr.2020.19 |